Specialities

Specialities

Adrenal Disorders
Bone Disorders
Cardiovascular Risk
COVID-19
Diabetes
Endocrine Oncology
General Endocrinology
Kidney Disorders
Obesity
Pediatric Endocrinology
Pituitary Disorders
Reproductive Endocrinology
Thyroid Disorders
Liver Disorders
Rare Disease Day
Search

Trending Topic

Glucose meter device with test strips and lancets on a blue textured background
14 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Clinical outcomes of tirzepatide in a real-world follow-up cohort of patients with type 2 diabetes

Thein M Tun, Muhammad Sabir, Hasanain Alismael

Type 2 diabetes (T2D) is a progressive metabolic condition associated with obesity, cardiovascular disease and substantial morbidity and mortality.1 Despite the availability of multiple glucose-lowering therapies, a significant proportion of individuals with T2D fail to achieve recommended glycemic targets, particularly those with long disease duration, obesity and insulin resistance.2,3 In parallel, excess adiposity remains a major driver of […]

touchREVIEWS in Endocrinology. 2026;22(2):Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
touchTALKS
CE/CME accredited

Unraveling the cortisol connection: Hard-to-control hypertension and hyperglycemia

Topics Covered:
Adrenal Disorders Cardiovascular Risk Diabetes Obesity Pituitary Disorders
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Downloads Tab
Claim Credit
Practice Aid
Slides
Audio Version
Add Note

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

Do you screen for hypercortisolism in patients with difficult-to-control diabetes or treatment-resistant hypertension?

Submit your answer to see the results and continue the video
Yes, always
   
Yes, but only if additional signs of excess cortisol are present
   
No, but I pursue further workup
   
No, this isn’t part of my current practice
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

How likely are you to consider cortisol excess in resistant HTN or hyperglycemia?

Submit your answer to see the results and continue the video
Very likely even without classic cushingoid features
   
Somewhat likely if additional clinical clues are present
   
Unlikely, I treat each condition separately
   
I wasn't aware cortisol excess could explain both
   

Tutorial

These icons indicate there is something to be interacted with. Click it when you see it.

Poll

What do you see as the biggest challenge to optimal care for patients with hypercortisolism?

Submit your answer to see the results and continue the video
Delayed diagnosis or missed recognition
   
Diagnostic complexity
   
Limited treatment options
   
Difficulty managing long-term comorbidities
   
Open Nav Add Note

Videos

Identifying hidden hypercortisolism in at-risk populations

Dr. Auchus describes the spectrum of hypercortisolism presentation and its link to multiple comorbidities, the prevalence of hidden hypercortisolism, and the impact of delayed diagnosis.
Duration: 12:34

Exploring the mechanistic role of cortisol excess in hyperglycemia and hypertension

Dr. Auchus explores the mechanisms that link hypercortisolism with hyperglycemia and hypertension, the cardiometabolic consequences of excess cortisol, and the benefit of cortisol reduction.
Duration: 11:36

Screening and management of cortisol-driven disease in at-risk populations

Dr. Auchus examines when and how to screen patients for hypercortisolism, management strategies for patients with excess cortisol, and best practices for monitoring and holistic care.
Duration: 14:26

Download

Download Slides

File Type: PDF File Size: 0.69 MB
Download

Download Practice Aid

File Type: PDF File Size: 0.6 MB
Download

Useful Tips

Select in the video player controls bar to choose subtitle language. Subtitles available in and Spanish Latin American.
Associated slides for this activity are available under the Downloads tab.
A practice aid for this activity is available under the Downloads tab.

Please complete the below form to claim your CME Credit.

Please rate your level of agreement by selecting the appropriate rating:

1
Strongly Disagree
5
Strongly Agree
*
Mandatory Field

Learning Objectives

  • Recognize patients at risk of hypercortisolism, especially those with refractory hypertension or hyperglycemia, and how underdiagnosis of hypercortisolism contributes to delayed intervention and increased morbidity
  • Describe the key mechanisms by which excess cortisol elevates blood pressure and glucose, and its role as a driver of cardiovascular and metabolic disease
  • Evaluate strategies to support the clinical recognition, diagnostic screening and management of hypercortisolism in at-risk patients with refractory hypertension or hyperglycemia

How has this activity informed future decisions? Please check all that apply:

Back to Activity
Next Step
Complete Step 1
Submit Feedback Submit Feedback
Complete Above Form

Please complete the below so we can prepare your certificate download.

touchTALKS

Unraveling the cortisol connection: Hard-to-control hypertension and hyperglycemia

0.75 CE/CME credit
Back
Submit Accreditation Submit Accreditation
Complete Above Form
touchENDOCRINOLOGY

Check your Inbox

We've sent your certificate

Back to Activity
Close Popup
touchENDOCRINOLOGY

Thank you
for your Feedback!

Back to Activity
Close Popup

Video Navigation

Videos

Identifying hidden hypercortisolism in at-risk populations

Dr. Auchus describes the spectrum of hypercortisolism presentation and its link to multiple comorbidities, the prevalence of hidden hypercortisolism, and the impact of delayed diagnosis.
Duration: 12:34

Exploring the mechanistic role of cortisol excess in hyperglycemia and hypertension

Dr. Auchus explores the mechanisms that link hypercortisolism with hyperglycemia and hypertension, the cardiometabolic consequences of excess cortisol, and the benefit of cortisol reduction.
Duration: 11:36

Screening and management of cortisol-driven disease in at-risk populations

Dr. Auchus examines when and how to screen patients for hypercortisolism, management strategies for patients with excess cortisol, and best practices for monitoring and holistic care.
Duration: 14:26

Listen on the Go

Listen on Amazon Music
Listen on Apple Podcasts
Listen on Spotify
Close Popup

Learning Objectives & Overview

Faculty & Disclosures

Downloads

Overview
Faculty
Downloads

Learning Objectives

After watching this activity, participants should be better able to:

  • Recognize patients at risk of hypercortisolism, especially those with refractory hypertension or hyperglycemia, and how underdiagnosis of hypercortisolism contributes to delayed intervention and increased morbidity
  • Describe the key mechanisms by which excess cortisol elevates blood pressure and glucose, and its role as a driver of cardiovascular and metabolic disease
  • Evaluate strategies to support the clinical recognition, diagnostic screening and management of hypercortisolism in at-risk patients with refractory hypertension or hyperglycemia

Overview

In this activity, renowned faculty Dr. Richard J. Auchus discusses how to recognize patients at risk of hypercortisolism; explains how excess cortisol drives hypertension, hyperglycemia, and cardiometabolic disease; and provides strategies for timely screening, diagnosis, and management of hypercortisolism.

This activity is supported by an independent educational grant from Corcept Therapeutics Incorporated.

Jointly provided by Partners for Advancing Clinical Education and touchIME.

read more

Target Audience

This activity has been designed to meet the educational needs of endocrinologists and primary care physicians involved in the management of hypercortisolism.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Dr. Richard J. Auchus discloses: Consultancy fees from Acerand Therapeutics, Aspect Biosystems, Astellas Pharmaceuticals, Blue Earth Diagnostics Ltd., Corcept Therapeutics, Crinetics Pharmaceuticals, H Lundbeck A/S, MSD, Neurocrine Biosciences, Neurocrine UK Ltd., Novo Nordisk, OMass Therapeutics, Quest Diagnostics, Recordati Rare Diseases, Sparrow Pharmaceuticals, Spruce Biosciences, Vertex Pharmaceuticals, and Xeris Pharmaceuticals. Grants/research support from Adrenas Therapeutics, Corcept Therapeutics, Crinetics Pharmaceuticals, H Lundbeck A/S, Mineralys Pharmaceuticals, Neurocrine Biosciences, Neurocrine UK Ltd., Recordati Rare Diseases, and Spruce Biosciences.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and touchIME. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For additional information about the accreditation of this activity, please visit https://partnersed.com

Date of original release: July 16, 2026. Date credits expire: July 16, 2027.

Estimated time to complete the activity 53 minutes

Faculty & Disclosures

Dr. Richard J. Auchus

University of Michigan, Ann Arbor, MI, USA
More Information
Close Popup

Dr. Richard J. Auchus

University of Michigan, Ann Arbor, MI, USA

Biography

Dr. Auchus is the James A. Shayman and Andrea S. Kevrick professor of translational medicine in the departments of pharmacology and internal medicine at the University of Michigan. He also serves as chief of the endocrinology section at the LTC Charles S. Kettles Veterans Affairs Healthcare System.

read more

Dr. Auchus and his group are active in a wide range of research projects, including basic biochemical principles and structural biology of steroid biosynthetic enzymes; comprehensive steroid mass spectrometry analysis; and clinical trials and translational investigation in disorders of the pituitary, adrenal, ovaries, and testes that cause hypertension, infertility, and obesity. His clinical interests also focus on pituitary, adrenal, and reproductive diseases that involve disorders of steroid production, and he is particularly interested in the care of adults with genetic disorders of steroid biosynthesis and action.

He has authored more than 390 journal articles and 40 book chapters, and he has lectured at a wide range of national and international conferences. He was elected to the Association of American Physicians in 2018 and was chosen to deliver the Lawson Wilkins lecture for the Pediatric Endocrine Society in 2022. He received the Frontiers in Science & Distinction in Endocrinology Award from the American Association of Clinical Endocrinology in 2023 and was the 2021 recipient of the Outstanding Clinical Investigator Award from the Endocrine Society.

Dr. Richard J. Auchus discloses: Consultancy fees from Acerand Therapeutics, Aspect Biosystems, Astellas Pharmaceuticals, Blue Earth Diagnostics Ltd., Corcept Therapeutics, Crinetics Pharmaceuticals, H Lundbeck A/S, MSD, Neurocrine Biosciences, Neurocrine UK Ltd., Novo Nordisk, OMass Therapeutics, Quest Diagnostics, Recordati Rare Diseases, Sparrow Pharmaceuticals, Spruce Biosciences, Vertex Pharmaceuticals, and Xeris Pharmaceuticals. Grants/research support from Adrenas Therapeutics, Corcept Therapeutics, Crinetics Pharmaceuticals, H Lundbeck A/S, Mineralys Pharmaceuticals, Neurocrine Biosciences, Neurocrine UK Ltd., Recordati Rare Diseases, and Spruce Biosciences.

Downloads2

View and download resources from this activity to support your learning and share with colleagues

Download Slides

File Type: PDF
File Size: 0.69 MB
Download

Download Practice Aid

File Type: PDF
File Size: 0.6 MB
Download

You Might Also Like9

Navigation Podcast Add Note

Video Navigation

Videos

Identifying hidden hypercortisolism in at-risk populations

Dr. Auchus describes the spectrum of hypercortisolism presentation and its link to multiple comorbidities, the prevalence of hidden hypercortisolism, and the impact of delayed diagnosis.
Duration: 12:34

Exploring the mechanistic role of cortisol excess in hyperglycemia and hypertension

Dr. Auchus explores the mechanisms that link hypercortisolism with hyperglycemia and hypertension, the cardiometabolic consequences of excess cortisol, and the benefit of cortisol reduction.
Duration: 11:36

Screening and management of cortisol-driven disease in at-risk populations

Dr. Auchus examines when and how to screen patients for hypercortisolism, management strategies for patients with excess cortisol, and best practices for monitoring and holistic care.
Duration: 14:26

Add a Note

Note Time: 00:00
Save Note
touchENDOCRINOLOGY
touchTALKS

This activity is for healthcare professionals in the USA.

This activity is supported by an independent educational grant from Corcept Therapeutics Incorporated.

Jointly provided by Partners for Advancing Clinical Education and touchIME.

Please select the profession that most closely matches your own:

Decline

Close Popup
touchENDOCRINOLOGY

Could not verify Country/IP Address.

We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.

Return to Homepage
touchENDOCRINOLOGY touchENDOCRINOLOGY

Register now for FREE access to

  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • Concise email updates and newsletters so you never miss out

This activity is supported by:

An independent medical education grant from Corcept Therapeutics Incorporated.

Jointly provided by Partners for Advancing Clinical Education and touchIME.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AMA PRA Category 1 Credit ™ expires: July 16, 2027

Latest Medical Education - straight to your inbox

Close Popup